​

Ultragenyx Pharmaceutical Ownership | Who Owns Ultragenyx Pharmaceutical?

OverviewForecastRevenueFinancialsChartTranscripts

Ultragenyx Pharmaceutical Ownership Summary

Ultragenyx Pharmaceutical is owned by 92.55% institutional investors, 3.13% insiders, and 4.33% retail investors. Vanguard group is the largest institutional shareholder, holding 10.29% of RARE shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 3.04% of its assets in Ultragenyx Pharmaceutical shares.

RARE Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockUltragenyx Pharmaceutical92.55%3.13%4.33%
SectorHealthcare Stocks 42.54%10.83%46.63%
IndustryBiotech Stocks 45.22%10.75%44.04%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Vanguard group10.13M10.29%$304.79M
Fmr7.28M7.40%$219.08M
Blackrock5.60M6.65%$230.30M
Blackrock funding, inc. /de6.43M6.53%$193.27M
Jpmorgan chase4.01M4.07%$120.66M
Sands capital management3.77M3.83%$113.40M
State street3.69M3.75%$111.07M
Rtw investments, lp3.26M3.31%$98.01M
Baker bros. advisors lp2.77M2.82%$83.40M
Price t rowe associates inc /md/2.31M2.35%$69.49M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Cutter capital management, lp406.80K7.01%$17.11M
Eagle health investments lp697.00K5.50%$20.97M
Blue owl capital lp422.44K3.94%$12.71M
B group135.00K2.99%$4.06M
Sphera funds management352.56K2.24%$10.60M
Rock springs capital management lp1.25M2.19%$37.49M
Palo alto investors lp369.53K2.06%$11.12M
Bioimpact capital395.70K1.95%$11.90M
Catalio capital management, lp291.26K1.62%$8.76M
Privium fund management b.v.289.80K1.57%$8.72M

Top Buyers

HolderShares% AssetsChange
Fmr7.28M0.01%4.68M
Rtw investments, lp3.26M1.21%1.55M
State street3.69M0.00%1.12M
Norges bank961.79K0.01%961.79K
Jpmorgan chase4.01M0.01%750.56K

Top Sellers

HolderShares% AssetsChange
Clearbridge investments155.75K0.00%-1.98M
Alkeon capital management---1.69M
Federated hermes496.06K0.03%-1.55M
Deep track capital, lp---1.35M
Alliancebernstein26.71K0.00%-1.23M

New Positions

HolderShares% AssetsChangeValue
Norges bank961.79K0.01%961.79K$40.46M
Braidwell lp588.70K0.53%588.70K$17.71M
Voloridge investment management482.58K0.05%482.58K$14.52M
Axa investment managers417.20K0.03%417.20K$12.55M
Yiheng capital management225.76K1.00%225.76K$6.79M

Sold Out

HolderChange
Stephens consulting-1.00
Twin peaks wealth advisors-3.00
Concourse financial group securities-3.00
True wealth design-5.00
Principal securities-7.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 2025316-7.87%91,125,125-3.19%921.01%174-2.79%92-9.80%
Jun 30, 20253386.29%94,259,1908.19%951.17%17810.56%100-2.91%
Mar 31, 2025319-4.20%88,821,8041.51%921.10%161-5.29%104-4.59%
Dec 31, 2024195-38.87%51,382,783-40.24%530.66%96-43.86%71-24.47%
Sep 30, 202431713.21%85,943,715-2.53%890.82%1724.88%9320.78%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard US Total Market Shares ETF2.81M3.04%92.60K
Vanguard Total Stock Mkt Idx Inv2.81M2.92%-59.32K
Sands Capital Select Growth TE Inst EQ2.39M2.53%-222.05K
Vanguard Small Cap Index2.18M2.26%-15.86K
Vanguard Explorer Inv2.03M2.15%30.03K
Strategic Advisers Fidelity US TtlStk1.67M1.74%1.61M
JPMorgan Mid Cap Growth I1.65M1.71%413.52K
Hartford MidCap Y1.28M1.39%-24.56K
JPM US Mid Cap Growth-Composite1.23M1.30%1.23M
Vanguard Small Cap Growth Index Inv1.23M1.28%-2.51K

Recent Insider Transactions

DateNameRoleActivityValue
Dec 10, 2025Horn Howard Chief Financial OfficerSell$112.09K
Oct 13, 2025Horn Howard Chief Financial OfficerSell$250.25K
Sep 18, 2025Huizenga Theodore Alan SVP, Chief Accounting OfficerSell$1.87K
Sep 12, 2025Parschauer Karah Herdman EVP and Chief Legal OfficerSell$76.37K
Sep 05, 2025Huizenga Theodore Alan SVP, Chief Accounting OfficerSell$2.64K

Insider Transactions Trends

DateBuySell
2025 Q4-2
2025 Q3-3
2025 Q2-3
2025 Q1-11
2024 Q4-3

RARE Ownership FAQ

Who Owns Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical shareholders are primarily institutional investors at 92.55%, followed by 3.13% insiders and 4.32% retail investors. The average institutional ownership in Ultragenyx Pharmaceutical's industry, Biotech Stocks , is 45.22%, which Ultragenyx Pharmaceutical exceeds.

Who owns the most shares of Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical’s largest shareholders are Vanguard group (10.13M shares, 10.29%), Fmr (7.28M shares, 7.40%), and Blackrock (5.6M shares, 6.65%). Together, they hold 24.34% of Ultragenyx Pharmaceutical’s total shares outstanding.

Does Blackrock own Ultragenyx Pharmaceutical?

Yes, BlackRock owns 6.65% of Ultragenyx Pharmaceutical, totaling 5.6M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 230.3M$. In the last quarter, BlackRock increased its holdings by 367.61K shares, a 7.02% change.

Who is Ultragenyx Pharmaceutical’s biggest shareholder by percentage of total assets invested?

Cutter capital management, lp is Ultragenyx Pharmaceutical’s biggest shareholder by percentage of total assets invested, with 7.01% of its assets in 406.8K Ultragenyx Pharmaceutical shares, valued at 17.11M$.

Who is the top mutual fund holder of Ultragenyx Pharmaceutical shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Ultragenyx Pharmaceutical shares, with 3.04% of its total shares outstanding invested in 2.81M Ultragenyx Pharmaceutical shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools